Acquisition includes wholly owned subsidiary businesses BioKey BV and BioClue BV. Platform is based on a proprietary biological discovery called HYFTâ„¢ patterns, signature sequences in DNA, RNA, and ...
ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and ...
New Platform Integrates Sequence Data and Information from Entire Biosphere Acquisition includes wholly owned subsidiary businesses BioKey BV and BioClue BV. Platform is based on a proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback